Table of Content

1. EXECUTIVE SUMMARY


2. INTRODUCTION
2.1. Overview of NAMPT Inhibitors
2.2. Key Historical Events Related to NAMPT Inhibitors
2.3. NAMPT Inhibitors: Recent Activity
2.4. NAMPT Inhibitors: Mechanism of Action
2.5. NAMPT Inhibitors: Key Target Indications


3. MARKET LANDSCAPE
3.1. NAMPT Inhibitors: Pipeline Review
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Type of Therapy
3.1.5. Analysis by Line of Treatment
3.1.5. Analysis by Route of Administration

3.2. NAMPT Inhibitors: Developer Landscape
3.2.1. Analysis by Type of Player
3.2.2. Analysis by Year of Establishment
3.2.3. Analysis by Location of Headquarters
3.2.4. Analysis by Location of Headquarters and Stage of Development
3.2.5. Analysis by Location of Headquarters and Phase of Development
3.2.6. Analysis by Location of Headquarters and Type of Molecule


4. PARTNERSHIPS AND COLLABORATIONS
4.1. NAMPT Inhibitors: Partnerships and Collaborations
4.1.1. Analysis by Year of Partnership
4.1.2. Analysis by Type of Partnership
4.1.3. Analysis by Year and Type of Partnership
4.1.4. Analysis by Type of Agreement
4.1.5. Analysis by Intercontinental and Intracontinental Deals
4.1.6. Active Players: Analysis by Number of Partnerships


5. FUNDING AND INVESTMENTS
5.1. NAMPT Inhibitors: Funding and Investments
5.1.1. Analysis of Instances by Year
5.1.2. Analysis of Amount Raised by Year
5.1.3. Analysis of Number of Instances Year and Type of Funding
5.1.4. Analysis of Amount Raised by Year and Type of Funding
5.1.5. Analysis of Number of Instances by Type of Funding
5.1.6. Analysis of Amount Raised by Type of Funding
5.1.7. Most Active Investors: Analysis by Number of Funding Instances

5.1.8. Active Players: Analysis by Number of Instances
5.1.9. Active Players: Analysis by Amount Raised
5.1.10. Analysis of Instances by Geography
5.1.11. Analysis of Total Amount Raised by Geography
5.1.12. Analysis of Total Amount Raised by Year of Establishment
5.1.13. Concluding Remarks


6. GRANTS ANALYSIS
6.1. Scope and Methodology
6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
6.2.1. Analysis of Instances by Year
6.2.2. Analysis of Amount Awarded by Year
6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
6.2.4. Prominent Program Officers: Analysis by Number of Grants
6.2.5. Analysis by Type of Recipient Organization
6.2.6. Analysis of Instances by Year
6.2.7. Analysis by Purpose of Grant Award
6.2.8. Analysis by Funding Institute
6.2.9. Analysis by Support Period
6.2.10. Analysis by Funding Institute and Support Period
6.2.11. Analysis by Activity Code
6.2.12. Analysis by Type of Application
6.2.13. Word Cloud of NIH Spending Categories


7. COMPANY COMPETITIVENESS
7.1. Key Assumptions and Parameters
7.2. Methodology
7.3. Benchmarking of Portfolio Strength
7.4. Benchmarking of Partnership Activity
7.5. Benchmarking of Funding Activity
7.6. Benchmarking of Portfolio Strength
7.7. NAMPT Inhibitors: Company Competitiveness Analysis


8. COMPANY PROFILES
8.1. Antengene Therapeutics
8.1.1. Company Overview
8.1.2. Funding Information
8.1.3. Product Portfolio
8.1.4. Recent Developments and Future Outlook

8.2. Aqualung Therapeutics
8.2.1. Company Overview
8.2.2. Funding Information
8.2.3. Product Portfolio
8.2.4. Patent Portfolio
8.2.5. Recent Developments and Future Outlook

8.3. Karyopharm Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.4. Patent Portfolio
8.3.5. Recent Developments and Future Outlook

8.4. OncoTartis
8.4.1. Company Overview
8.4.2. Funding Information
8.4.3. Product Portfolio
8.4.4. Patent Portfolio
8.4.5. Recent Developments and Future Outlook

8.5. Onxeo
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook


9. PUBLICATION ANALYSIS
9.1. Methodology and Key Parameters
9.2. NAMPT Inhibitors: List of Publications
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Most Popular Journals: Analysis by Number of Publications
9.2.4. Most Popular Publishers: Analysis by Number of Publications
9.2.5. Analysis by Journal Impact Factor
9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
9.2.7. Analysis by Geography
9.2.8. Emerging Focus Areas


10. GLOBAL EVENTS ANALYSIS
10.1. Methodology and Key Parameters
10.2. NAMPT Inhibitors: List of Global Events
10.2.2. Cumulative Year-wise Trend
10.2.3. Analysis by Type of Event
10.2.4. Analysis by Event Platform
10.2.5. Leading Players: Analysis by Number of Participants
10.2.6. Leading Presenters: Analysis by Number of Participants
10.2.7. Analysis by Geography


11. SOCIAL MEDIA ANALYSIS
11.1. Methodology and Key Parameters
11.1.1. Cumulative Year-wise Activity
11.1.2. Leading Users: Analysis by Number of Tweets
11.1.3. Trending Words / Phrases on Twitter


12. DRUG FAILURE ANALYSIS
12.1. Methodology and Key Parameters
12.2. NAMPT Inhibitors: List of Failed Drug Candidates
12.2.1. Analysis by Phase of Discontinuation
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Target Indication
12.2.4. Analysis by Route of Administration
12.2.5. Analysis by Type of Sponsor
12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
12.2.7. Analysis by Reasons for Drug Failure
12.2.8. Key Terms in Study Results
12.2.9. Other Plausible Reasons for Drug Failure


13. FDA APPROVAL STRATEGIES
13.1. Methodology and Key Parameters
13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
13.3. Drug Specific Business Models followed by Company
13.4. Analysis of Drug Candidates by Business Model


14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Key Assumptions and Parameters
14.2. Forecast Methodology
14.3. Global NAMPT Inhibitors Market, 2027-2040
14.4. List of Forecasted Drugs
14.4.1. OT-82, OncoTartis
14.4.1.1. Global Sales Forecast
14.4.1.2. Regional Sales Forecast
14.4.1.3. Net Present Value
14.4.1.4. Value Creation Analysis

14.4.2. ALT-100, Aqualung Therapeutics
14.4.2.1. Global Sales Forecast
14.4.2.2. Regional Sales Forecast
14.4.2.3. Net Present Value
14.4.2.4. Value Creation Analysis

14.4.3. ATG-019, Antengene Therapeutics
14.4.3.1. Global Sales Forecast
14.4.3.2. Regional Sales Forecast
14.4.3.3. Net Present Value
14.4.3.4. Value Creation Analysis

14.4.4. KPT-9274, Karyopharm Therapeutics
14.4.4.1. Global Sales Forecast
14.4.4.2. Regional Sales Forecast
14.4.4.3. Net Present Value
14.4.4.4. Value Creation Analysis

14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040

14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040

14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040

14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040

14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040

14.10. NAMPT Inhibitors: Market Share of Key Players
14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: LIST OF FIGURES

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS